Robotic type II B posterior exenteration for recurrent vaginal cancer
Wafa Khadraoui(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Gulden Menderes(Yale University), Levent Mutlu(Yale University), Burak Zeybek(University of Florida)
Cited by 5
Related Papers
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
|Scientific Reports|2020|60
Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer
|JAMA Network Open|2023|41
“More than a song and dance”: Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok
|Gynecologic Oncology|2023|15
Port-Site Metastasis in Gynecological Malignancies
|JSLS Journal of the Society of Laparoscopic & Robotic Surgeons|2021|11
ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis
|Journal of Extracellular Biology|2024|11